U.S. Markets close in 3 hrs 55 mins

AVEO Pharmaceuticals, Inc. (AVEO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.98+0.03 (+1.33%)
As of 12:05PM EDT. Market open.
People also watch
Full screen
Previous Close1.95
Bid1.94 x 14300
Ask1.95 x 1100
Day's Range1.71 - 2.04
52 Week Range0.50 - 2.11
Avg. Volume2,595,767
Market Cap287.8M
PE Ratio (TTM)-5.20
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • AVEO's Kidney Cancer Candidate Gets CHMP Recommendation
    Zacks3 hours ago

    AVEO's Kidney Cancer Candidate Gets CHMP Recommendation

    AVEO Pharmaceuticals, Inc. (AVEO) announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its lead candidate, Fotivda (tivozanib), for the treatment of advanced renal cell carcinoma (RCC).

  • MarketWatch4 days ago

    AVEO Pharma surges 48% on recommendation for European approval of its cancer drug

    AVEO Pharmaceuticals Inc. shares surged as much as 48% in extremely heavy morning trade Friday after the company's cancer drug was recommended for approval in Europe. The decision was made by a scientific ...

  • Reuters4 days ago

    EU regulators greenlight U.S. biotech Aveo's kidney cancer drug

    European regulators on Friday recommended the approval of Aveo Pharmaceuticals Inc's drug to treat kidney cancer, marking a big victory for the U.S. biotech that has faced a number of setbacks in bringing the drug to the market. The European Medicines Agency (EMA) said experts at its Committee for Medicinal Products for Human Use (CHMP) had backed the oral, once-daily drug for marketing approval as a first-line treatment for advanced renal cell carcinoma, or kidney cancer. The drug was also backed for treating adult patients with advanced kidney cancer who met certain criteria and had received one prior treatment with cytokine therapy, the EMA said.